Peptide

Histrelin (Supprelin LA)

FDA-approved product existsGH axis & hormones
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is Histrelin (Supprelin LA)?

FDA-approved histrelin is marketed as Supprelin LA, a 12-month implant for children with central precocious puberty.

Dosing as published

Approved labelSUPPRELIN LA prescribing information for central precocious puberty
PopulationPediatric patients covered by the approved SUPPRELIN LA indication
DoseOne 50 mg implant releasing approximately 65 mcg daily
RouteSubcutaneous implant in the inner upper arm
FrequencyReplace every 12 months
DurationAnnual replacement while treatment remains indicated
PreparationSterile 50 mg implant supplied for insertion by a trained healthcare professional; not reconstituted.
Source: Dosage and Administration section 2; Dosage Forms and Strengths section 3

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved
Last checked2026-07-13
Next review2026-10-11

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.